To include your compound in the COVID-19 Resource Center, submit it here.

RoActemra regulatory update

The U.K.'s NICE said it needs additional information before it can recommend the use of Roche's RoActemra tocilizumab to treat systemic juvenile idiopathic arthritis

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE